First-in-Human cancer antibody trial begins
NCT ID NCT03191682
Summary
This is the first study to test a new antibody drug called PRL3-ZUMAB in people. The goal is to find a safe dose for patients with advanced solid tumors or blood cancers that have stopped responding to standard treatments. Researchers will give increasing doses to small groups of patients to monitor for side effects and see if the drug shows any early signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore, 119.074, Singapore
Conditions
Explore the condition pages connected to this study.